eCOA for Autoimmune Clinical Trials
Flare diaries, automated disease activity scoring, and endpoint data you can defend.
eCOA for autoimmune clinical trials is the electronic capture of symptom, flare, disease activity, and quality-of-life data from participants, clinicians, and caregivers. YPrime builds flare diaries, automated disease activity scoring, and protocol logic into a single validated platform, supporting global autoimmune studies from early phase through pivotal programs and long-term extensions.
Autoimmune diseases fluctuate. Symptoms flare and remit between scheduled visits, so a study that relies on visit-day recall alone captures an incomplete picture of the patient experience.
Autoimmune protocols also depend on composite disease activity assessments scores that determine eligibility, drive treatment decisions, and define endpoints. When those scores are calculated by hand at the site, at the end of a long visit, variability enters the endpoint data.
eCOA addresses both problems. It moves symptom capture closer to when symptoms occur, and it moves scoring into the workflow, so raters observe and the system calculates.
Why Autoimmune Trials
Require Specialized eCOA
Maintaining consistency across sites while collecting complete, reliable data requires more than electronic questionnaires. It requires technology that supports the way autoimmune trials actually operate.
YPrime combines nearly two decades of eCOA experience with global deployment expertise, instrument knowledge, and flexible study design to help sponsors navigate that complexity.
Capture flare activity, pain, fatigue, and other symptoms closer to when participants experience them
Build disease activity and severity scoring into the workflow to reduce manual effort and support consistency across sites
Connect eCOA, IRT, and eConsent through a single partner for a seamless experience for participants, sites, and study teams
Proven in Global
Autoimmune Study
YPrime supports autoimmune clinical trials across a broad range of dermatologic, rheumatologic, gastrointestinal, and systemic conditions. Our experience includes global studies where symptom reporting, quality-of-life assessments, and disease activity scores play an important role in eligibility determination, treatment decisions, and endpoint evaluation.
Case Study: eCOA for Ulcerative Colitis
Confirming a qualifying disease flare is rarely simple, and in one global Phase 2/3 Ulcerative Colitis study, it required combining site-entered data, patient-reported diaries, and procedure-linked findings into a single eligibility determination. YPrime’s eCOA platform supported that workflow across more than 250 sites, 25+ countries, and 3,000+ patients.
Eligibility combined patient-collected baseline symptom data gathered at home, site review and acceptance of that baseline, and flare severity scoring timed to protocol-defined bowel prep and endoscopy windows, with data from site entry, tablet, and handheld devices reconciled into one auditable determination. YPrime supplied that underlying eligibility data directly, supporting independent review of each decision separate from the treating site.
Across a 3-questionnaire eCOA diary deployed to thousands of patients, the platform showed how flexible eCOA can support even the most layered eligibility requirements without disrupting trial execution.
How YPrime Supports
Autoimmune Studies
YPrime delivers flexible eCOA and IRT solutions for global autoimmune clinical trials, supporting studies from early phase through pivotal programs and long-term extensions.
Our approach is designed around the realities of autoimmune research, where symptoms fluctuate, protocols evolve, and study teams need consistent data across sites and regions.
Support for validated symptom, function, and health-related quality-of-life assessments, including indication-specific instruments
Automated scoring and protocol logic that help sites manage disease activity calculations, eligibility assessments, and study workflows
Daily and event-driven flare diaries designed to capture symptom changes and disease activity between scheduled visits
Efficient deployment of protocol amendments across sites and devices while maintaining version control and audit readiness
Global language support, translation management, and instrument licensing expertise for multinational autoimmune studies
eCOA Designed for
Participants, Sponsors,
and Sites
Long-term autoimmune studies depend on consistent, reliable data collection across participants, sites, and study milestones.
Participants need assessments that are easy to complete, sites need workflows that reduce administrative burden, and sponsors need reliable symptom, function, and quality-of-life data alongside clinical and laboratory measures.
When data collection fits naturally into study workflows, studies run more efficiently and generate the high-quality evidence needed to evaluate treatment effectiveness with confidence.
Power Your Next
Autoimmune Clinical Trial
Whether you’re planning a rheumatoid arthritis, psoriasis, atopic dermatitis, Crohn’s, or inflammatory bowel disease study, success depends on collecting high quality data while maintaining operational consistency across sites and regions.
YPrime’s eCOA and IRT solutions are designed to work together, helping sponsors create a more connected experience for participants and sites while maintaining the flexibility and oversight complex autoimmune clinical trials require.
FAQS
FAQs
What is eCOA in autoimmune clinical trials?
eCOA (electronic Clinical Outcome Assessment) is the digital collection of clinical trial outcome data, replacing paper-based processes. In autoimmune clinical trials, eCOA is commonly used to collect symptom data, flare diaries, clinician assessments, disease activity measures, and health-related quality-of-life outcomes, helping improve data quality and reduce missing entries.
Why is eCOA important in autoimmune clinical trials?
Autoimmune diseases often fluctuate between scheduled visits. eCOA enables participants and sites to record symptom and assessment data closer to when it occurs, helping reduce recall-related variability and improve the consistency of endpoint data. eCOA also supports standardized workflows and audit-ready documentation throughout the study lifecycle.
What autoimmune assessments can be supported through eCOA?
YPrime’s eCOA platform supports symptom, function, and quality-of-life assessments, daily and event-driven flare diaries, clinician-reported outcomes, and indication-specific instruments used across autoimmune indications, including but not limited to psoriasis, rheumatoid arthritis, atopic dermatitis, Crohn’s, and inflammatory bowel disease.
How does eCOA support disease activity and severity scoring?
Scoring logic can be built directly into the assessment workflow. Site personnel enter assessment data, and the system applies study-specific calculation rules to generate composite disease activity and severity scores while maintaining complete traceability and documentation.
Can eCOA support protocol changes during an autoimmune study?
Yes. YPrime’s configurable platform is designed to support protocol amendments throughout the study lifecycle, deploying updates across sites and devices while maintaining version control and audit readiness.
Can eCOA and IRT work together in an autoimmune clinical trial?
Yes. YPrime offers both eCOA and IRT solutions, helping sponsors create connected study workflows across participant data collection, trial execution, and treatment management. A coordinated approach can help improve visibility, simplify study operations, and support a more seamless experience for sites and participants.